Gwynne Dyer

Gwynne Dyer

All the usual caveats apply: don’t go out and celebrate, don’t let your guard down, it’s still going to be a long haul. This winter will be “hard”, warned Ugur Sahin, co-founder and CEO of BioNTech, the German company that announced the first effective Covid-19 vaccine only a week ago. It can’t be rolled out fast enough to reduce infections much in the current wave, he said.

The publication last Monday of positive results for a second vaccine, this time by the US company Moderna, strengthened the optimism. Clearly, this coronavirus can be beaten, and there are nine more potential Covid vaccines already in third-stage (final) human trials.

But again, the riders: there will be at least half a million more Covid deaths this winter—or over a million if people don’t observe the lockdowns and other restrictions meant to contain the spread of the virus. “What is absolutely essential,” said Sahin, “is that we get a high vaccination rate before autumn/winter next year.” That’s when it could really be over.

And yet there is cause to celebrate, because of the 11 vaccine candidates that were already in third-stage trials, both the front-runners are “messenger ribonucleic acid” (mRNA) vaccines—an entirely new approach that allows a much faster response to novel viral infections.

Traditionally, new vaccines took around ten years to be developed, tested and approved for general use. For the new mRNA vaccines, it has been ten months.

After Chinese scientists posted the full genetic sequence of the Covid-19 virus online on January 10, said Drew Weissman of the University of Pennsylvania, “we were making RNA within a week or so”. Weissman then supplied that RNA to both BioNTech/Pfizer (Pfizer is a large American company that gives the German innovators US distribution and regulatory clout) and Moderna.

RNA carries the genetic instructions from the nucleus of the cell to build whatever protein is needed, and for the past decade researchers have been trying to fabricate “messenger” RNA that could be inserted into human cells. The mRNA would then use the cell’s own genetic machinery to make vaccines and other medically useful proteins.

By 2018, several companies had cracked the problem of getting the mRNA past the body’s immune defences. With the full RNA sequence of the new coronavirus in their possession, all they had to do was choose which bit of the coronavirus RNA to use in the vaccine.

Obviously not the whole thing, or it would rebuild the entire virus in the cell. Just a harmless segment of the virus’s RNA, copied millions of times by the vaccinated person’s cells, would alert the body’s immune system and train it to destroy any invading virus with that sequence. (They chose the “spike” that the virus uses to attach itself to the human cell.)

Several companies had mRNA vaccines ready for testing within two or three months, and the results have been spectacular. BioNTech/Pfizer has just reported 95 per cent efficacy for its vaccine, and last weekend Moderna reported 94.5 per cent.

Even better, both BioNTech/Pfizer and Moderna included all major ethnic groups and

a significant number of elderly people in their third-phase trials. All categories responded well to the vaccines (which is not always the case with other vaccines).

Yet another mRNA vaccine in third-phase trials could be even better, because it will be far cheaper than the BioNTech/Pfizer vaccine (US$39 for two shots) or the Moderna jab (US$74 for two shots) if it pans out. At Imperial College in London, Robin Shattock’s team is working on a “self-amplifying RNA” vaccine that may require as little as one-hundredth of the amount of vaccine.

The mRNA technique may mean future pandemics can be dealt with far more quickly. The vehicle is already available and waiting to carry the next vaccine. Just “plug and play” for any future coronavirus, as one researcher put it. (We have had three new coronaviruses in the past two decades.)

Pfizer boss Albert Boura went even further: “It’s the greatest medical advance in the past 100 years.” Well, maybe, though a vote taken today would probably plump for antibiotics instead. But we are only beginning to see the potential of mRNA.

There are already trials under way for a wide variety of other illnesses: not just safer, more effective influenza, polio and HIV vaccines, but immunotherapies for cancer, heart conditions, cystic fibrosis and other systemic and congenital diseases. There is a long, dark winter still ahead of us, no doubt, but miracles may await us over the horizon. And we can now be sure that the light at the end of this particular tunnel is not an oncoming train.

RECOMMENDED FOR YOU

I CRY SHAME on the United National Congress (UNC) for causing the defeat of the Anti-Gang Bill in the House of Representatives. The UNC leadership will pay a heavy political price with the non-aligned voters for withholding their support for the UNC.

IT always escapes my logic, both from a practical sense and a political sense as to why the Opposition chooses to adopt as its strategy, the non-support of anti-crime bills.

I would think it’s just good politics to be hard on crime.

The history of the trade union movement in Trinidad and Tobago would be totally incomplete and unfinished if the life and times of Tubal Uriah “Buzz” Butler are not the DNA of such a history. Butler was accredited as being the “Chief Servant of the Lord”. He believed that man’s purpose in life was the fulfilment of God’s purpose and as such, he owed no obligation to anybody or anything but to God..

THE negative responses from residents who are expecting to be dislocated by the Government’s East Port of Spain development plan suggest the need for meaningful dialogue and consultation with affected communities and the wider national community.

The fact that such consultation appears not to have been built into the plan is a worrying indicator. In this day and age, community engagement is a critical and standard aspect of public planning, especially for heritage areas, such as Piccadilly, and others, like Sea Lots in this case, where residents developed entire communities out of waste land.

I think more than enough time has passed for us to discuss national issues based on appreciating the facts, rather than just promoting divisiveness and ignorance.

Please allow me to comment on three things, perhaps insignificant, but nevertheless, three things that caught my eye over the last few days. But first, a preamble.

In this Covid-19 period, there is very little for elderly people like myself to do, so we wait eagerly for the news, through the dailies, and of course, on TV.

To be honest, today’s reports can be rather depressing, except of course, the good news about a 94.5 per cent success rate of a vaccine against his dreaded virus.

To be honest, it’s the 5.5 per cent balance that troubles me. You know, it’s like those liquids that kill 99 per cent of household germs; who measures the 1 per cent? Anyway, better than nothing.